NYSE:HIMSHealthcare
Hims Novo Nordisk GLP-1 Launch Ties Growth Story To Valuation Gap
Hims & Hers Health (NYSE:HIMS) has launched access to Novo Nordisk FDA-approved GLP-1 medications for eligible patients.
The offering includes a range of GLP-1 options, including the only pill currently approved for weight loss.
The company also introduced a new weight loss membership that combines medication access with broader support services.
Hims & Hers Health focuses on telehealth and subscription based care, and GLP-1 weight loss treatments have become a key area of interest for both...